Eledon PharmaceuticalsELDN
Market Cap: $98.3M
About: Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and for patients living with ALS. The company's compound in development is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential.
Employees: 20
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
600% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 2
152% more capital invested
Capital invested by funds: $19.8M [Q1] → $49.8M (+$30M) [Q2]
75% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 4
10% more funds holding
Funds holding: 29 [Q1] → 32 (+3) [Q2]
9.32% more ownership
Funds ownership: 39.66% [Q1] → 48.97% (+9.32%) [Q2]
Research analyst outlook
We haven’t received any recent analyst ratings for ELDN.